1406.Hk
The company operates in the healthcare sector, primarily engaged in pharmaceuticals and healthcare facilities and services, generating revenue through the provision of healthcare-related products and services.
Business. The company operates in the healthcare sector, primarily engaged in pharmaceuticals and healthcare facilities and services, generating revenue through the provision of healthcare-related products and services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare sector, primarily engaged in pharmaceuticals and healthcare facilities and services, generating revenue through the provision of healthcare-related products and services.
The company's capital structure is characterized by a low debt-to-equity ratio of 0.13, indicating a conservative leverage position. It maintains a strong liquidity position with a current ratio of 4.41, supported by cash and equivalents of HKD 141.43 million. However, the company reported negative operating cash flow of HKD -15.58 million and free cash flow of HKD -71.22 million, suggesting operational cash generation challenges.
Profitability metrics are concerning, with a return on equity of -0.3999 and a return on assets of -0.3209, both significantly below the industry median for healthcare facilities and services. The company reported a net loss of HKD -75.79 million and an operating loss of HKD -79.87 million, indicating a need for operational improvements to align with industry benchmarks.
The company's revenue is concentrated in the pharmaceuticals segment, with no disclosed geographic breakdown. This concentration may expose the company to specific market risks, particularly in the healthcare sector, where regulatory and demand fluctuations can significantly impact performance.
Looking ahead, the company's growth trajectory is uncertain. While it reported revenue of HKD 190.93 million, the lack of positive operating cash flow and profitability metrics suggests a challenging path to growth. The outlook for the current fiscal year does not indicate a significant improvement in revenue or profitability.
Risk factors include the company's negative operating and free cash flows, which could affect its ability to fund operations and invest in growth. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. However, the company's negative net income and operating income suggest a need for careful monitoring of its financial health.
Recent events, including filings and transcripts, have not indicated any significant developments that would alter the company's current financial or operational status. The company remains in a position where it must address its profitability and cash flow issues to sustain operations and growth.
- The company has a strong liquidity position with a current ratio of 4.41, supported by HKD 141.43 million in cash and equivalents.
- Profitability is a major concern, with a return on equity of -0.3999 and a return on assets of -0.3209, both significantly below industry medians.
- The company's revenue is concentrated in the pharmaceuticals segment, which may expose it to specific market risks.
- Growth is uncertain due to negative operating and free cash flows, with no significant improvement expected in the current fiscal year.
- Risk factors include negative operating and free cash flows, but liquidity and dilution risks are currently low.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 1406.HK Market data — financials · 2026-05-26